$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000032001713000009 Filed on March 11, 2013

Income Statement

Concept	2013 Q1	2011 Q4	2011 Q1
Revenue	$2.524K	$4.210M	$19.59M
YoY Change	-99.93%	-76.75%	23.76%
Cost Of Revenue	$2.392M	$3.310M	$14.28M
YoY Change	-19.07%	-77.41%	31.58%
Gross Profit	$131.8K	$900.0K	$5.314M
YoY Change	-83.87%	-73.91%	6.72%
Gross Profit Margin	5222.78%	21.38%	27.13%
Selling, General & Admin	$5.802M	$6.390M	$9.635M
YoY Change	-9.52%	-19.11%	53.18%
% of Gross Profit	4401.26%	710.0%	181.3%
Research & Development	$3.161M	$2.060M	$2.755M
YoY Change	62.35%	-19.84%	111.94%
% of Gross Profit	2398.16%	228.89%	51.84%
Depreciation & Amortization	$550.0K	$220.0K	$2.200M
YoY Change	41.03%	-91.47%	185.71%
% of Gross Profit	417.23%	24.44%	41.4%
Operating Expenses	$11.36M	$8.460M	$12.39M
YoY Change	35.84%	-19.27%	63.24%
Operating Profit	-$8.831M	-$7.560M	-$7.076M
YoY Change	17.09%	7.54%	171.1%
Interest Expense	$43.56K	-$590.0K	$852.2K
YoY Change	-91.69%	28.26%	-8622.43%
% of Operating Profit
Other Income/Expense, Net	-$32.95K	$510.0K	-$1.103M
YoY Change	-92.45%	6.25%	589.18%
Pretax Income	-$8.864M	-$7.630M	-$8.178M
YoY Change	11.09%	9.0%	194.18%
Income Tax	$0.00	$0.00	$592.6K
% Of Pretax Income
Net Earnings	-$8.801K	-$18.85M	-$10.17M
YoY Change	-99.91%	205.02%	120.67%
Net Earnings / Revenue	-348.69%	-447.74%	-51.93%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.269M	-$16.11M	-$13.74M
COMMON SHARES
Basic Shares Outstanding	168.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2011 Q4	2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.300M	$3.900M	$9.400M
YoY Change	-57.34%	-75.0%	-25.4%
Cash & Equivalents	$9.254M	$3.935M	$9.412M
Short-Term Investments			$0.00
Other Short-Term Assets	$2.500M	$33.00M	$166.2K
YoY Change	-10.71%	650.0%	-97.32%
Inventory	$1.542M	$647.7K	$26.20M
Prepaid Expenses
Receivables	$886.2K	$1.010M	$7.100M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.68M	$38.61M	$50.40M
YoY Change	-76.07%	-17.65%	20.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.79M	$11.62M	$11.76M
YoY Change	-77.19%	2567.32%	-52.79%
Goodwill	$11.12M	$11.12M	$7.014M
YoY Change	-43.47%
Intangibles	$14.33M	$15.09M	$5.700M
YoY Change	-60.5%	2577.83%
Long-Term Investments
YoY Change
Other Assets	$979.1K	$3.327M	$581.9K
YoY Change	-84.12%	18.9%	190.95%
Total Long-Term Assets	$37.22M	$116.7M	$125.4M
YoY Change	-67.44%	21.4%	56.36%
TOTAL ASSETS
Total Short-Term Assets	$12.68M	$38.61M	$50.40M
Total Long-Term Assets	$37.22M	$116.7M	$125.4M
Total Assets	$49.90M	$155.3M	$175.8M
YoY Change	-70.17%	8.6%	44.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.191M	$2.287M	$12.40M
YoY Change	-88.7%	284.05%	39.33%
Accrued Expenses	$1.683M	$1.090M	$4.100M
YoY Change	-50.94%	51.32%	241.67%
Deferred Revenue
YoY Change
Short-Term Debt	$3.400M	$3.600M	$4.700M
YoY Change	-82.47%	20.0%	113.64%
Long-Term Debt Due	$100.0K	$100.0K	$14.70M
YoY Change	-66.67%	-98.96%	16.67%
Total Short-Term Liabilities	$9.228M	$36.45M	$40.90M
YoY Change	-80.42%	10.81%	31.09%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$4.800M	$6.400M
YoY Change	-97.62%	-26.15%	-53.28%
Other Long-Term Liabilities	$275.4K	$0.00	$540.5K
YoY Change	-98.9%	-100.0%	-92.79%
Total Long-Term Liabilities	$11.66M	$33.94M	$540.5K
YoY Change	-65.88%	98.29%	-97.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.228M	$36.45M	$40.90M
Total Long-Term Liabilities	$11.66M	$33.94M	$540.5K
Total Liabilities	$20.89M	$70.38M	$110.8M
YoY Change	-74.31%	40.75%	20.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$206.2M	-$143.1M
YoY Change	35.16%	50.12%
Common Stock	$170.3K	$109.3K
YoY Change	31.1%	71.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$665.6K	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.42M	$62.03M	$65.00M
YoY Change
Total Liabilities & Shareholders Equity	$49.90M	$155.3M	$175.8M
YoY Change	-70.17%	8.6%	44.1%

Cashflow Statement

Concept	2013 Q1	2011 Q4	2011 Q1
OPERATING ACTIVITIES
Net Income	-$8.801K	-$18.85M	-$10.17M
YoY Change	-99.91%	205.02%	120.67%
Depreciation, Depletion And Amortization	$550.0K	$220.0K	$2.200M
YoY Change	41.03%	-91.47%	185.71%
Cash From Operating Activities	-$7.136M	-$3.410M	-$10.20M
YoY Change	-438.76%	-35.66%	295.16%
INVESTING ACTIVITIES
Capital Expenditures	$53.57K	-$60.00K	$707.2K
YoY Change	-59.41%	-98.45%	-118.81%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.140M	-$2.400M
YoY Change	-100.0%	-151.35%	179.07%
Cash From Investing Activities	-$53.57K	$1.080M	-$3.105M
YoY Change	-51.33%	-117.73%	-32.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.705M	3.550M	7.081M
YoY Change	-62.35%	-84.48%	-38.22%
NET CHANGE
Cash From Operating Activities	-$7.136M	-3.410M	-10.20M
Cash From Investing Activities	-$53.57K	1.080M	-3.105M
Cash From Financing Activities	$2.705M	3.550M	7.081M
Net Change In Cash	-$4.484M	1.220M	-6.219M
YoY Change	-148.83%	-89.37%	-245.99%
FREE CASH FLOW
Cash From Operating Activities	-$7.136M	-$3.410M	-$10.20M
Capital Expenditures	$53.57K	-$60.00K	$707.2K
Free Cash Flow	-$7.189M	-$3.350M	-$10.90M
YoY Change	-464.12%	134.27%	-1023.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2287201	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2555240	USD
CY2011Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1370900	USD
CY2011Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	451400	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1053604	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1010475	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2284813	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1090176	USD
CY2012Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2284.8	USD
CY2011Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1090.2	USD
CY2011Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	240.0	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	606.6	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1267600	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2022500	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4152343	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2011	us-gaap	Additional Information About Entitys Reportable Segments AdditionalInformationAboutEntitysReportableSegments	three reportable segments
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	231071236	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200858638	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10266000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6712500	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	626054	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	187600	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1609495	USD
CY2011	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2440241	USD
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	577300	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	605200	USD
CY2012Q4	us-gaap	Assets Assets	54406263	USD
CY2011Q4	us-gaap	Assets Assets	155327780	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	38610336	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	16707216	USD
CY2012Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	23800300.0	USD
CY2011Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	32367217	USD
CY2012Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2012Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Noncurrent AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	USD
CY2011Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Noncurrent AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	75570645	USD
CY2011Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	9874000	USD
CY2012Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	9897800	USD
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	7550000	USD
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	3130000	USD
CY2012	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	-4420000	USD
CY2011	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	0	USD
CY2011Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	98300	USD
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	99500	USD
CY2011Q1	us-gaap	Cash Cash	227900	USD
CY2012	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2011	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	320863	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3935160	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13737452	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	12745432	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	15612391	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	13737452	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	992020	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2866959	USD
CY2012Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	800000	USD
CY2011Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	800000	USD
CY2012	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-8370228	USD
CY2011	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	2739496	USD
CY2011	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1803182	USD
CY2012	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-5660305	USD
CY2011	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	845206	USD
CY2012	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	4907407	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	7950107	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	163753653	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109329587	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109329587	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	163753653	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	109330	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	163754	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52057723	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45761192	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-8215026	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-12448950	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-53976218	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-70521654	USD
CY2011	us-gaap	Cost Of Revenue CostOfRevenue	8646687	USD
CY2012Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2011Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	11949124	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-175533	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2011Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5596600	USD
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3311800	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1468341	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1121134	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	169198	USD
CY2012Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	6644500	USD
CY2011Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	USD
CY2011Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	408200	USD
CY2012Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	391800	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	23100	USD
CY2011Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	212900	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	35545600	USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	16928200	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	22524800	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	38857400	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25727700	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17816700	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5466700	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3917400	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	48500	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	15200	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	13800	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	107300	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	239700	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18441900.0	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2317900.0	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3599100	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3774700	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3311800.0	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3303000.0	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3774655	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3599122	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	2138500	USD
CY2012	us-gaap	Depreciation Depreciation	1000000	USD
CY2011	us-gaap	Depreciation Depreciation	900000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1550571	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1440576	USD
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	101156	USD
CY2011Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	474463	USD
CY2011Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	8810272	USD
CY2012Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	0	USD
CY2011	us-gaap	Dividends Dividends	11726099	USD
CY2011Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3000000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2011	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	46245	USD
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	14389	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	365.7	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1597.2	USD
CY2009Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.51
CY2012Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.51
CY2011	us-gaap	Extraordinary Item Net Of Tax ExtraordinaryItemNetOfTax	9448000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1288200	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	683000	USD
CY2012	us-gaap	Finite Lived Intangible Assets Future Amortization Expense FiniteLivedIntangibleAssetsFutureAmortizationExpense	14500	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14480800	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15086000	USD
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	683700	USD
CY2011Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	632400	USD
CY2012	us-gaap	Future Amortization Expense After Year Five FutureAmortizationExpenseAfterYearFive	11500	USD
CY2012	us-gaap	Future Amortization Expense Year Five FutureAmortizationExpenseYearFive	600	USD
CY2012	us-gaap	Future Amortization Expense Year Four FutureAmortizationExpenseYearFour	600	USD
CY2012	us-gaap	Future Amortization Expense Year One FutureAmortizationExpenseYearOne	600	USD
CY2012	us-gaap	Future Amortization Expense Year Three FutureAmortizationExpenseYearThree	600	USD
CY2012	us-gaap	Future Amortization Expense Year Two FutureAmortizationExpenseYearTwo	600	USD
CY2011	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-13653	USD
CY2012Q4	us-gaap	Goodwill Goodwill	11117770	USD
CY2011Q4	us-gaap	Goodwill Goodwill	11117770	USD
CY2011Q1	us-gaap	Goodwill Goodwill	7013500	USD
CY2012	us-gaap	Gross Profit GrossProfit	2380765	USD
CY2011	us-gaap	Gross Profit GrossProfit	1403399	USD
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-35814140	USD
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-34266544	USD
CY2011	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-299789	USD
CY2012	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-287181	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34566333	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36276854	USD
CY2011	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-34566333	USD
CY2012	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-36101321	USD
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.39
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.26
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22016524	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-30267990	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-12312646	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-9148599	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-17955344	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-12867925	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.15
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.13
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-175533	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	525700	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	2852100	USD
CY2012	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2011	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-72400	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12005500.0	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12334100.0	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-384800	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2177000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2154100	USD
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	1119500	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	2100000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	443132	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	554884	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	178008	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	948452	USD
CY2012	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	36000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	465280	USD
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	647745	USD
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-53211	USD
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2414842	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	178011	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	350227	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-2596	USD
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15086038	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14480827	USD
CY2011Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5700000	USD
CY2012	us-gaap	Interest Expense InterestExpense	1576975	USD
CY2011	us-gaap	Interest Expense InterestExpense	2647692	USD
CY2011	us-gaap	Interest Paid InterestPaid	1522700	USD
CY2012	us-gaap	Interest Paid InterestPaid	1771800	USD
CY2012	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	182000	USD
CY2011	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	384300	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	1113025	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	647745	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6712536	USD
CY2011	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	10266023	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1523700	USD
CY2011	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1713600	USD
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	702000	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	654500	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54406263	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155327780	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9949427	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36446644	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33937292	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11636677	USD
CY2012Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	28165010	USD
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	26388976	USD
CY2012Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	171528	USD
CY2011Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2011Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	17900	USD
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	39500	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	18106961	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	-356970	USD
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">The Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;"> fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. We anticipate that cellular therapies will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Progenitor Cell Therapy, LLC, our wholly owned subsidiary (“PCT”), is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011, is developing our own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents our most clinically advanced therapeutic product candidate and enrollment for our Phase 2 PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (“AMI”) patients commenced in 2012. We expect to complete enrollment for this study in 2013 with the first data readout available six to eight months thereafter.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and position the Company to capture a meaningful share of the worldwide AMI market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. We plan to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat type 1 diabetes, graft vs. host disease, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection and expect to file an Investigational New Drug Application ("IND") with the FDA in 2013 and commence human clinical studies in one of these disease conditions thereafter.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our pre-clinical assets include our VSEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> TM</sup></font><font style="font-family:inherit;font-size:10pt;"> (Very Small Embryonic Like) Technology platform for which we expect to file an IND with the FDA in late 2013 or early 2014 to initiate an National Institutes of Health ("NIH") funded human clinical studies treating periodontitis with VSELs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">. We are also working on a Department of Defense funded study of VSELs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;"> and mesenchymal stem cells for the treatment of chronic wounds.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level allowing our developing a network to scale rapidly if the demand grows. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, we operated our business in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three reportable segments</font><font style="font-family:inherit;font-size:10pt;">: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. In 2012, we exited our operations in China. Effective March 31, 2012, we no longer operated in the Regenerative Medicine – China reportable segment, which is now reported in discontinued operations (see Note 16). On November 13, 2012, we completed the sale of our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">51%</font><font style="font-family:inherit;font-size:10pt;"> interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 16). As a result, we currently operate in a single reporting segment - Cell Therapy, which will focus on CDMO and cell therapy development programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) and include the accounts of the Company and its wholly owned and partially owned subsidiaries, the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 16), and the operations of our former Pharmaceutical Manufacturing - China reporting segment through November 13, 2012, the date on which the segment was sold (see Note 16). In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, include all normal and recurring adjustments considered necessary to present fairly the Company's financial position as of December 31, 2012 and 2011, and the results of its operations and its cash flows for the periods presented. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below, as well as the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 16), and the operations of our former Pharmaceutical Manufacturing - China reporting segment through November 13, 2012, representing the date which the segment was sold (see Note 16). These former segments are reported in discontinued operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="32%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage of Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parent  Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Therapies, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stem Cell Technologies, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amorcyte, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CBH Acquisition LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">China Biopharmaceuticals Holdings, Inc. (CBH)*  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by CBH Acquisition LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progenitor Cell Therapy, LLC (PCT)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Family Storage, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Athelos Corporation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.1% owned by PCT</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT Allendale, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* The 51% interest in Erye formerly held by our subsidiary CBH was sold on November 13, 2012.</font></div></div>
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20069370	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8741769	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17329874	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17111997	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2054580	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6088380	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11748685	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-251398	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20927994	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13852518	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18759925	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-21773200	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-53769484	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-47134469	USD
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	69700000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47774234	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55310326	USD
CY2011	us-gaap	Noncash Contribution Expense NoncashContributionExpense	607363	USD
CY2012	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-561822	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5891203	USD
CY2011Q4	us-gaap	Notes Payable NotesPayable	148100	USD
CY2012Q4	us-gaap	Notes Payable NotesPayable	374100	USD
CY2011Q4	us-gaap	Notes Payable Current NotesPayableCurrent	148062	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	202558	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	35407910	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	32766416	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-34004511	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-30385651	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3592900	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	563900	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	713700	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	878800	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1143300	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	293200	USD
CY2012	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	25994800
CY2012Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	8800000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	81.0	USD
CY2011Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	484.5	USD
CY2011Q1	us-gaap	Other Assets Current OtherAssetsCurrent	166200	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	947307	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3326938	USD
CY2011Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	581900	USD
CY2011	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	2596987	USD
CY2012	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	385905	USD
CY2011	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2606639	USD
CY2012	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	405021	USD
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	2606639	USD
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	-4152343	USD
CY2011	us-gaap	Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	0	USD
CY2012	us-gaap	Other Comprehensive Income Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	6014981	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	214871	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2011Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	540500	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4314228	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2085870	USD
CY2011	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-562000	USD
CY2012	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	5394263	USD
CY2011Q3	nbs	Procceds From Sale Of Stock Net ProccedsFromSaleOfStockNet	14800000	USD
CY2011	nbs	Shares Of Preferred Stock And Warrants For Common Stock Issued SharesOfPreferredStockAndWarrantsForCommonStockIssued	3000000	shares
CY2011	nbs	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1300000	USD
CY2011	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	650000	USD
CY2012	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	235000	USD
CY2012	us-gaap	Payments Of Dividends PaymentsOfDividends	327748	USD
CY2011	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
CY2012	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3100000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	574857	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	531315	USD
CY2011	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	639765	USD
CY2012	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	528023	USD
CY2012	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	528023	USD
CY2011	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	639765	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2351558	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	649739	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	803135	USD
CY2012	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	12280000	USD
CY2011	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16428827	USD
CY2011	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	21152682	USD
CY2011	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	149766	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	666501	USD
CY2011	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	2500000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7100	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6604418	USD
CY2011	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2011	us-gaap	Profit Loss ProfitLoss	-56582857	USD
CY2012	us-gaap	Profit Loss ProfitLoss	-66369311	USD
CY2012	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13175600	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12883700	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11153143	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11616053	USD
CY2011Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11755000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1559100	USD
CY2012Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1800600	USD
CY2012	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	440477	USD
CY2011	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	180132	USD
CY2011	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3000000	USD
CY2012	us-gaap	Revenues Revenues	14329889	USD
CY2011	us-gaap	Revenues Revenues	10050086	USD
CY2012	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	196585	USD
CY2011	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	149542	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7720748	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10451070	USD
CY2012	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2011	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1150000	USD
CY2011	us-gaap	Restatement Of Prior Year Income Net Of Tax RestatementOfPriorYearIncomeNetOfTax	1367300	USD
CY2012	us-gaap	Restatement Of Prior Year Income Net Of Tax RestatementOfPriorYearIncomeNetOfTax	321600	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143094854	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197392361	USD
CY2012	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1117901	USD
CY2011	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	0	USD
CY2010Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.945
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3438475	USD
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3635061	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22315346	USD
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27687162	USD
CY2011	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	3467451	shares
CY2012	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	2295533	shares
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21152682	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16428827	USD
CY2011	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3580600	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1325100	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6712536	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10266023	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7100	USD
CY2012	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1117901	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	33177129	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	62025557	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32820159	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80132518	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86487619	USD
CY2012Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	0.00
CY2011Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	1.00
CY2011Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10582011	shares
CY2012Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2011Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	6662748	shares
CY2011Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6662748	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3135411	shares
CY2012Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	0	USD
CY2011Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	4811326	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	665600	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2012	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	373307	USD
CY2011	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2096904	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	39144700	USD
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	20702900	USD
CY2012Q3	nbs	Base Monthly Rent Expense Of Executive Offices BaseMonthlyRentExpenseOfExecutiveOffices	27000	USD
CY2012Q3	nbs	Base Monthly Rent Expense Of Subleases BaseMonthlyRentExpenseOfSubleases	7500	USD
CY2012	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	3500000	USD
CY2011	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	2600000	USD
CY2012	nbs	Common Stock Issued In Payment Of Dividends For Convertible Redeemable Series E7 Preferred Stock CommonStockIssuedInPaymentOfDividendsForConvertibleRedeemableSeriesE7PreferredStock	3400000	USD
CY2012	nbs	Common Stock Issued To Acquire Businesses CommonStockIssuedToAcquireBusinesses	0	USD
CY2011	nbs	Common Stock Issued To Acquire Businesses CommonStockIssuedToAcquireBusinesses	17200000	USD
CY2012	nbs	Common Stock Warrants And Contingent Consideration Issued With Acquisition Of Amorcyte CommonStockWarrantsAndContingentConsiderationIssuedWithAcquisitionOfAmorcyte	0	USD
CY2011	nbs	Common Stock Warrants And Contingent Consideration Issued With Acquisition Of Amorcyte CommonStockWarrantsAndContingentConsiderationIssuedWithAcquisitionOfAmorcyte	8483400	USD
CY2010Q4	nbs	Common Stock Warrants Shares CommonStockWarrantsShares	21843507	shares
CY2011Q4	nbs	Common Stock Warrants Shares CommonStockWarrantsShares	37389825	shares
CY2012Q4	nbs	Common Stock Warrants Shares CommonStockWarrantsShares	55287611	shares
CY2011	nbs	Contributions From Noncontrolling Interests ContributionsFromNoncontrollingInterests	1150000	USD
CY2011Q4	nbs	Deferred Tax Liabilities Accumulated Depreciation DeferredTaxLiabilitiesAccumulatedDepreciation	155100	USD
CY2012Q4	nbs	Deferred Tax Liabilities Accumulated Depreciation DeferredTaxLiabilitiesAccumulatedDepreciation	348700	USD
CY2011	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	748900	USD
CY2012	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	175700	USD
CY2012	nbs	Income Tax Reconciliation Undistributed Foreign Earnings IncomeTaxReconciliationUndistributedForeignEarnings	-1810300	USD
CY2011	nbs	Income Tax Reconciliation Undistributed Foreign Earnings IncomeTaxReconciliationUndistributedForeignEarnings	1810300	USD
CY2011	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-486952	USD
CY2012	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	1677551	USD
CY2011	nbs	Issuance Of Common Stock In Connection With Preferred Stock Settlement Value IssuanceOfCommonStockInConnectionWithPreferredStockSettlementValue	3620300	USD
CY2012	nbs	Issuance Of Common Stock In Connection With Preferred Stock Settlement Value IssuanceOfCommonStockInConnectionWithPreferredStockSettlementValue	674194	USD
CY2012	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	1026600	USD
CY2011	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	3511200	USD
CY2011Q1	nbs	Mortgages Payable MortgagesPayable	3784600	USD
CY2012Q2	nbs	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2012Q2	nbs	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2012	nbs	Other Comprehensive Income Foreign Currency Translation Elimination On Sale Of Segment OtherComprehensiveIncomeForeignCurrencyTranslationEliminationOnSaleOfSegment	-10402352	USD
CY2011	nbs	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Elimination On Exit Of Segment OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationEliminationOnExitOfSegment	0	USD
CY2012	nbs	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Elimination On Exit Of Segment OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationEliminationOnExitOfSegment	-169993	USD
CY2012	nbs	Payment For Warrant Inducement PaymentForWarrantInducement	228676	USD
CY2011	nbs	Payment For Warrant Inducement PaymentForWarrantInducement	0	USD
CY2009Q4	nbs	Percentage Of Additional Paid In Capital PercentageOfAdditionalPaidInCapital	0.45
CY2009Q4	nbs	Percentage Of Distributed Profit PercentageOfDistributedProfit	0.06
CY2009Q4	nbs	Percentage Of Undistributed Profit PercentageOfUndistributedProfit	0.49
CY2011	nbs	Permanent Non Deductible Expenses For Us Taxes PermanentNonDeductibleExpensesForUSTaxes	5907300	USD
CY2012	nbs	Permanent Non Deductible Expenses For Us Taxes PermanentNonDeductibleExpensesForUSTaxes	-2781400	USD
CY2010Q4	nbs	Preferred Offering Units PreferredOfferingUnits	10582011	shares
CY2011Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2012Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2011Q3	nbs	Procceds From Sale Of Stock Gross ProccedsFromSaleOfStockGross	16500000	USD
CY2012	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	-511755	USD
CY2011	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	87773	USD
CY2011	nbs	Stock Issued During Period Shares Warrant Inducements StockIssuedDuringPeriodSharesWarrantInducements	670000	shares
CY2012	nbs	Stock Issued During Period Shares Warrant Inducements StockIssuedDuringPeriodSharesWarrantInducements	419690	shares
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2011	nbs	Stock Issued During Period Value Amorcyte Merger StockIssuedDuringPeriodValueAmorcyteMerger	5353400	USD
CY2011	nbs	Stock Issued During Period Value Charitable Contribution StockIssuedDuringPeriodValueCharitableContribution	607363	USD
CY2011	nbs	Stock Issued During Period Value Pct Merger StockIssuedDuringPeriodValuePctMerger	17200000	USD
CY2012	nbs	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	6604419	USD
CY2012	nbs	Stock Issued During Period Value Warrant Inducements StockIssuedDuringPeriodValueWarrantInducements	-228676	USD
CY2011	nbs	Supplemental Dividends From Subsidiaries SupplementalDividendsFromSubsidiaries	11726100	USD
CY2012	nbs	Supplemental Dividends From Subsidiaries SupplementalDividendsFromSubsidiaries	0	USD
CY2012	nbs	Warrant Inducements WarrantInducements	1012819	USD
CY2011	nbs	Warrant Inducements WarrantInducements	0	USD
CY2011	nbs	Warrants Canceled WarrantsCanceled	0	shares
CY2012	nbs	Warrants Canceled WarrantsCanceled	1318644	shares
CY2012	nbs	Warrants Exercised WarrantsExercised	11076182	shares
CY2011	nbs	Warrants Exercised WarrantsExercised	0	shares
CY2011	nbs	Warrants Expired WarrantsExpired	447629	shares
CY2012	nbs	Warrants Expired WarrantsExpired	790003	shares
CY2011	nbs	Warrants Granted WarrantsGranted	15993947	shares
CY2012	nbs	Warrants Granted WarrantsGranted	31082615	shares
CY2012	nbs	Warrants Issued During Period Value WarrantsIssuedDuringPeriodValue	172200	USD
CY2011	nbs	Warrants Issued During Period Value WarrantsIssuedDuringPeriodValue	495100	USD
CY2011Q4	nbs	Weighted Average Common Shares Outstanding WeightedAverageCommonSharesOutstanding	88599000	shares
CY2011	nbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	1.03
CY2012	nbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	0.58
CY2011	nbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	0
CY2012	nbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	4.60
CY2011	nbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0
CY2012	nbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0.60
CY2011	nbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	6.18
CY2012	nbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	2.17
CY2011	nbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	2.09
CY2012	nbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	0.57
CY2012Q4	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	1.57
CY2010Q4	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	2.62
CY2011Q4	nbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	2.35
CY2011	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	88598696	shares
CY2012	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	138419965	shares
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	168412155	shares
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q2	dei	Entity Public Float EntityPublicFloat	66100000	USD
CY2012	dei	Entity Registrant Name EntityRegistrantName	NeoStem, Inc.

Files In Submission

Name	View Source	Status
0000320017-13-000009-index-headers.html	Edgar Link	pending
0000320017-13-000009-index.html	Edgar Link	pending
0000320017-13-000009.txt	Edgar Link	pending
0000320017-13-000009-xbrl.zip	Edgar Link	pending
exh1043.htm	Edgar Link	pending
exh1057.htm	Edgar Link	pending
exh211.htm	Edgar Link	pending
exh231.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nbs-10kx20121231.htm	Edgar Link	pending
nbs-20121231.xml	Edgar Link	completed
nbs-20121231.xsd	Edgar Link	pending
nbs-20121231_cal.xml	Edgar Link	unprocessable
nbs-20121231_def.xml	Edgar Link	unprocessable
nbs-20121231_lab.xml	Edgar Link	unprocessable
nbs-20121231_pre.xml	Edgar Link	unprocessable
nbs-ex311_20121231xq4.htm	Edgar Link	pending
nbs-ex312_20121231xq4.htm	Edgar Link	pending
nbs-ex321_20121231xq4.htm	Edgar Link	pending
nbs-ex322_20121231xq4.htm	Edgar Link	pending
neostemlogohires.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
theneostempyramid.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2013 Q1 Form 10-K Financial Statement

#000032001713000009 Filed on March 11, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2013 Q1 Form 10-K Financial Statement

#000032001713000009 Filed on March 11, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta